Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor Kumar Jeetendra | October 2, 2020 Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients. Panthera Chairman …
Moderna COVID-19 antibody seems safe, gives indications of working in more seasoned grown-ups: Study Kumar Jeetendra | September 30, 2020 Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those found in younger adults, with side effects about on par with high-dose flu shots, researchers said on Tuesday. The study, published in the New England Journal of Medicine, offers …
GlaxoSmithKline CEO hopeful COVID-19 immunization generally accessible in 2021 Kumar Jeetendra | September 30, 2020 The chief executive of GlaxoSmithKline, the world’s largest maker of vaccines, said she was convinced that the industry will have the ability to make an immunisation against COVID-19 widely available next year. “I share the optimism that we’ll have solutions next year. The challenge here is getting into the scale that’s required,” GSK CEO Emma …
Johnson and Johnson’s COVID-19 immunization produces solid invulnerable reaction in early preliminary Kumar Jeetendra | September 26, 2020 Pharmaceutical giant Johnson & Johnson’s experimental COVID-19 vaccine has produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, in accordance with the data published on September 25. “The data demonstrate that a single dose of COVID-19 vaccine, Ad26.COV2.S, induced a powerful neutralising antibody response in nearly all participants aged …
Zydus Cadila gets USFDA gesture for numerous sclerosis treatment drug Kumar Jeetendra | September 26, 2020 Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing. Zydus Cadila said in its approval, the USFDA noted that Zydus …
Cipla receives final approval for generic version of Biogen IDEC Inc.’s Tecfidera® Kumar Jeetendra | September 25, 2020 Mumbai, India; September 25, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pak from the United States Food and Drug Administration (US FDA). Cipla’s …
Hamdard Laboratories strengthen its medicine portfolio; launches six new Unani medicines for overall wellness Kumar Jeetendra | September 24, 2020 New Delhi, September 24, 2020: To strengthen its wellness medicine product portfolio, Hamdard Laboratories (Medicine Division), a progressive research-based health and wellness organization launched six new OTC (over the counter) medicines to treat illness like fever, cold, cough, etc. The newly launched medicines are developed from ancient Unani formulations that combine the benefits of time-tested …
India preliminaries for Russia’s ‘Sputnik-V’ antibody may start in next barely any weeks: Dr Reddy’s Kumar Jeetendra | September 22, 2020 Reddy’s Laboratories Ltd could start late-stage Indian clinical trials of Russia’s potential coronavirus vaccine within the next few months, an executive in the Indian drugmaker said on Tuesday. Indian trials of this Sputnik-V vaccine candidate, being developed by Russia’s sovereign wealth fund, will enroll 1,000-2,000 participants and also be conducted at multiple private and government …
BDR Pharma to launch 80mg of Enzalutamide for treatment of Prostate Cancer in India Kumar Jeetendra | September 21, 2020 Mumbai 21st September 2020: BDR Pharmaceutical today announces the launch of 80mg advanced version of its Enzalutamide drug. BDR Pharma had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40mg Enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name BDENZA. The 80 mg …
Aurobindo Pharma ties up with BIRAC to create COVID-19 immunization Kumar Jeetendra | September 17, 2020 Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine. Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. “Aurobindo is in the process of preparing a state-of-art manufacturing facility …
Dr Reddy’s’ settles case with Bristol Myers Squibb unit over nonexclusive malignant growth drug Kumar Jeetendra | September 17, 2020 The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential …
Dr Reddy’s accomplices with RDIF to convey 100 million doses of Sputnik V antibody in India Kumar Jeetendra | September 16, 2020 Hyderabad, Sep 16 (PTI) The Russian Direct Investment Fund (RDIF), Russias autonomous wealth finance, and Dr Reddys Laboratories Ltd. have agreed to collaborate on clinical trials and supply of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine, Dr Reddys stated in …
